Table 5.

Adverse events in the TACE-Atez/Bev group

Adverse Event	All Events	CTCAE Grade
		1	2	3
Hypertension	13 (21.0%)	6 (9.7%)	5 (8.1%)	2 (3.2%)
Proteinuria	6 (9.7%)	4 (6.5%)	2 (3.2%)	0 (0%)
Fatigue	4 (6.5%)	3 (4.8%)	1 (1.6%)	0(0%)
Diarrhea	3 (4.8%)	2 (3.2%)	1 (1.6%)	0 (0%)
Gastrointestinal hemorrhage	2 (3.2%)	2 (3.2%)	0 (0%)	0 (0%)

CTCAE Common Terminology Criteria for Adverse Events, Atez/Bev Atezolizumab/bevacizumab, TACE Transarterial chemoembolization